Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company focused on developing therapies for hematological malignancies, has scheduled its full year 2024 financial results announcement and corporate update for March 27, 2025.
The company will host two investor events: an English conference call and webcast at 8:00 am EDT/8:00 pm HKT on March 27, and a Chinese (Mandarin) investor event at 9:30 am HKT on March 28. Both events will include Q&A sessions with management and will be available for replay on the company's website for 30 days.
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), un'azienda biopharmaceutica globale focalizzata sullo sviluppo di terapie per le neoplasie ematologiche, ha programmato l'annuncio dei suoi risultati finanziari per l'intero anno 2024 e un aggiornamento aziendale per il 27 marzo 2025.
L'azienda ospiterà due eventi per investitori: una conferenza telefonica in inglese e un webcast alle 8:00 EDT/20:00 HKT del 27 marzo, e un evento per investitori in cinese (mandarino) alle 9:30 HKT del 28 marzo. Entrambi gli eventi includeranno sessioni di domande e risposte con il management e saranno disponibili per la riproduzione sul sito web dell'azienda per 30 giorni.
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), una compañía biofarmacéutica global enfocada en desarrollar terapias para malignidades hematológicas, ha programado el anuncio de sus resultados financieros del año completo 2024 y una actualización corporativa para el 27 de marzo de 2025.
La compañía llevará a cabo dos eventos para inversores: una conferencia telefónica en inglés y un webcast a las 8:00 a.m. EDT/8:00 p.m. HKT el 27 de marzo, y un evento para inversores en chino (mandarín) a las 9:30 a.m. HKT el 28 de marzo. Ambos eventos incluirán sesiones de preguntas y respuestas con la dirección y estarán disponibles para reproducción en el sitio web de la compañía durante 30 días.
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855)는 혈액암 치료제 개발에 주력하는 글로벌 생명공학 회사로, 2024년 전체 재무 결과 발표 및 기업 업데이트를 2025년 3월 27일로 예정하고 있습니다.
회사는 두 개의 투자자 이벤트를 개최할 예정입니다: 3월 27일 오전 8시 EDT/오후 8시 HKT에 영어 컨퍼런스 콜 및 웹캐스트, 그리고 3월 28일 오전 9시 30분 HKT에 중국어(만다린) 투자자 이벤트입니다. 두 이벤트 모두 경영진과의 질의응답 세션이 포함되며, 회사 웹사이트에서 30일 동안 재생할 수 있습니다.
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), une entreprise biopharmaceutique mondiale axée sur le développement de thérapies pour les malignités hématologiques, a prévu l'annonce de ses résultats financiers pour l'année 2024 et une mise à jour de l'entreprise pour le 27 mars 2025.
L'entreprise organisera deux événements pour investisseurs : une conférence téléphonique et un webcast en anglais à 8h00 EDT/20h00 HKT le 27 mars, et un événement pour investisseurs en chinois (mandarin) à 9h30 HKT le 28 mars. Les deux événements comprendront des sessions de questions-réponses avec la direction et seront disponibles en replay sur le site web de l'entreprise pendant 30 jours.
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), ein globales biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für hämatologische Malignome konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das gesamte Jahr 2024 und ein Unternehmensupdate für den 27. März 2025 angesetzt.
Das Unternehmen wird zwei Investorenveranstaltungen ausrichten: eine englische Telefonkonferenz und einen Webcast um 8:00 Uhr EDT/20:00 Uhr HKT am 27. März sowie eine chinesische (Mandarin) Investorenveranstaltung um 9:30 Uhr HKT am 28. März. Beide Veranstaltungen beinhalten eine Fragerunde mit dem Management und sind für 30 Tage auf der Unternehmenswebsite verfügbar.
- None.
- None.
ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT).
Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by the Ascentage management team.
The English conference call and webcast will be held at 8:00 am EDT / 8:00 pm HKT on March 27, 2025. To access the English conference call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the English conference call will be available on the Ascentage Pharma website at: Full Year 2024 Financial Results.
Ascentage will host a Chinese (Mandarin) investor event at 9:30 am HKT on Friday, March 28, 2025 (9:30 pm EDT on Thursday, March 27, 2025), which will also be available simultaneously via conference call and webcast. To access the Chinese investor event or conference call, please register in advance here.
The webcast replay for both conference calls will also be available on the News & Events page of the Ascentage Pharma website and will be archived for 30 days.
About Ascentage Pharma
Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market under the ticker symbol “AAPG” since January 2025.
Contacts
Investor Relations
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
Hogan.Wan@ascentage.com
+86 512 85557777
Stephanie Carrington
ICR Healthcare
Stephanie.Carrington@icrhealthcare.com
(646) 277-1282
Media Relations
Sean Leous
ICR Healthcare
Sean.Leous@icrhealthcare.com
(646) 866-4012
FAQ
When will Ascentage Pharma (AAPG) release its 2024 financial results?
How can investors join AAPG's 2024 financial results conference call?
Will AAPG's 2024 financial results presentation be available in multiple languages?
How long will AAPG's 2024 financial results webcast be available for replay?
